Clinical Trial Detail

NCT ID NCT02530489
Title Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

triple-receptor negative breast cancer

Therapies

Atezolizumab + Nab-paclitaxel

Age Groups: senior adult

No variant requirements are available.